TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation

Non-genotoxic reactivation of the p53 pathway by MDM2-p53 binding antagonists is an attractive treatment strategy for wild-type TP53 cancers. To determine how resistance to MDM2/p53 binding antagonists might develop, SJSA-1 and NGP cells were exposed to growth inhibitory concentrations of chemically...

Descripción completa

Detalles Bibliográficos
Autores principales: Drummond, Catherine J., Esfandiari, Arman, Liu, Junfeng, Lu, Xiaohong, Hutton, Claire, Jackson, Jennifer, Bennaceur, Karim, Xu, Qing, Makimanejavali, Aditya Rao, Bello, Fabio Del, Piergentili, Alessandro, Newell, David R., Hardcastle, Ian R., Griffin, Roger J., Lunec, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216791/
https://www.ncbi.nlm.nih.gov/pubmed/27323823
http://dx.doi.org/10.18632/oncotarget.10073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216791/
https://www.ncbi.nlm.nih.gov/pubmed/27323823
http://dx.doi.org/10.18632/oncotarget.10073

Ejemplares similares